SHARE:  
Join Our Email List
Update: Candida auris Cases in Kindred Hospital, Santa Ana
March 28, 2019
Multiple patients colonized with Candida auris ( C. auris ) have been identified recently at Kindred Hospital, Santa Ana. These patients are the first identified in Southern California.

OCHCA has followed up on all patients discharged from Kindred Hospital, Santa Ana since February 1, 2019.  For all patients who currently reside at a hospital or skilled nursing facility, OCHCA has contacted that patient’s facility and provided recommendations to institute appropriate infection control measures and arrange C. auris screening.

Updated Recommendations:

  • All healthcare facilities should perform admission screening for C. auris and institute empiric Contact precautions for patients admitted from Kindred Hospital, Santa Ana. Patients who have been previously screened at Kindred, Santa Ana should still have admission screening performed at the accepting facility.

  • Admission screening for C. auris should include a composite swab of the axilla and groin as well as a swab of the nares. The CDC recommends inclusion of swabbing of the nares to optimize testing yield. 

  • Hospitals accepting patients from Kindred Hospital, Santa Ana should contact OCHCA at 714-834-8180 to arrange for receipt of screening swabs and coordinate their transfer to a public health laboratory for testing.  Testing for C. auris colonization is available through the Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Laboratory Network. At this time, commercial testing for C. auris screening is not available. C. auris colonization testing by culture generally takes 7-21 days to result.

  • Facility-to-facility communication is critical when transferring a patient who is suspected or confirmed to be colonized or infected with C. auris. Any accepting facility should be made aware of the patient’s status.

  • Hospitals that frequently share patients with Kindred Hospital, Santa Ana are currently recommended to perform species identification of all clinical Candida isolates, regardless of specimen source. OCHCA has contacted the affected facilities regarding this recommendation. Enhanced Candida speciation will help assure identification of C. auris. No additional surveillance or infection control measures are recommended for these hospitals at this point.  

  • Facilities that do not frequently share patients with Kindred Hospital, Santa Ana are not currently recommended to change their laboratory testing or surveillance practices.
Background:
C. auris is an emerging yeast that is multidrug resistant and has a propensity to spread in healthcare settings. Outbreaks have occurred in several states, primarily in the eastern half of the country. One case was identified in Northern California in 2018. Early detection of C. auris and rigorous adherence to infection control measures is essential for containing its spread in healthcare facilities.
Infection Control: 
Appropriate infection control precautions for patients suspected or confirmed to be colonized or infected with C. auris include:
  • Place patient in a single-patient room and use Standard and Contact Precautions.
  • Emphasize adherence to hand hygiene.
  • Use dedicated medical equipment.
  • Minimize the number of healthcare staff caring for the patient.
  • Clean and disinfect the patient care environment and reusable equipment (daily and terminal cleaning) with recommended products (see below) throughout the unit or facility where patients with C. auris are located.

Patients have remained colonized for several months, even after an active infection has resolved. The maximum amount of time that a patient can be colonized is unknown. There are currently no data on the efficacy of decolonization for patients with C. auris , such as the use of chlorhexidine or topical antifungals.
Laboratory Testing:
C. auris has been identified from many body sites including bloodstream, urine, respiratory tract, biliary fluid, wounds, and external ear canal. The CDC recommends that all yeast isolates obtained from a normally sterile site (e.g., bloodstream, cerebrospinal fluid) be identified to the species level so that appropriate initial treatment can be administered based on the typical, species-specific susceptibility patterns. In addition, yeast isolates obtained from non-sterile sites (e.g., urine, respiratory tract) can be identified to the species level as part of enhanced surveillance for C. auris .
Cleaning Agents:
  CDC recommends the use of an Environmental Protection Agency (EPA)-registered hospital-grade disinfectant effective against Clostridioides difficile spores (List K, found at https://www.epa.gov/pesticide-registration/list-k-epas-registered-antimicrobial-products-effective-against-clostridium ). Quaternary ammonium compounds that are routinely used for disinfection may not be effective against C. auris , and data on use of hands-free disinfection methods, like germicidal UV irradiation, are limited. 
Treatment:
Consultation with an infectious disease specialist is highly recommended for patients infected with C. auris . Echinocandins should be used for initial treatment in most cases. See CDC's guidance for more detailed treatment information.

For additional information, visit https://www.cdc.gov/fungal/candida-auris/index.html
Contact Information
Healthcare facilities or laboratories that suspect they have a patient with C. auris infection should contact the Orange County Health Care Agency Epidemiology and Assessment Program immediately at 714-834-8180.
If you do not currently receive our Provider Advisories you can add yourself to our email list via the button below.